Free Trial

Avenue Therapeutics (ATXI) Competitors

Avenue Therapeutics logo
$0.42 +0.06 (+17.06%)
As of 03:57 PM Eastern

ATXI vs. MTNB, VIVS, RDHL, CNSP, DRMA, THAR, SNGX, SPRB, CMND, and REVB

Should you be buying Avenue Therapeutics stock or one of its competitors? The main competitors of Avenue Therapeutics include Matinas Biopharma (MTNB), VivoSim Labs (VIVS), Redhill Biopharma (RDHL), CNS Pharmaceuticals (CNSP), Dermata Therapeutics (DRMA), Tharimmune (THAR), Soligenix (SNGX), Spruce Biosciences (SPRB), Clearmind Medicine (CMND), and Revelation Biosciences (REVB). These companies are all part of the "pharmaceutical products" industry.

Avenue Therapeutics vs. Its Competitors

Matinas Biopharma (NYSE:MTNB) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Matinas Biopharma is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Matinas BiopharmaN/AN/A-$22.94M-$3.86-0.25
Avenue TherapeuticsN/AN/A-$10.38M-$7.49-0.06

Matinas Biopharma's return on equity of -123.06% beat Avenue Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Matinas BiopharmaN/A -123.06% -94.28%
Avenue Therapeutics N/A -471.57%-296.50%

Matinas Biopharma has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, Avenue Therapeutics has a beta of -0.08, indicating that its share price is 108% less volatile than the S&P 500.

In the previous week, Avenue Therapeutics had 17 more articles in the media than Matinas Biopharma. MarketBeat recorded 17 mentions for Avenue Therapeutics and 0 mentions for Matinas Biopharma. Matinas Biopharma's average media sentiment score of 0.00 beat Avenue Therapeutics' score of -0.19 indicating that Matinas Biopharma is being referred to more favorably in the media.

Company Overall Sentiment
Matinas Biopharma Neutral
Avenue Therapeutics Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Matinas Biopharma
0 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

11.8% of Matinas Biopharma shares are held by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are held by institutional investors. 4.6% of Matinas Biopharma shares are held by insiders. Comparatively, 1.8% of Avenue Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Matinas Biopharma beats Avenue Therapeutics on 7 of the 11 factors compared between the two stocks.

Get Avenue Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATXI vs. The Competition

MetricAvenue TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.34M$815.77M$5.52B$9.41B
Dividend YieldN/A4.84%3.80%4.04%
P/E Ratio0.021.4128.0419.84
Price / SalesN/A25.49429.5399.59
Price / CashN/A19.5635.8457.94
Price / Book0.226.878.125.65
Net Income-$10.38M-$4.17M$3.25B$258.00M
7 Day Performance15.07%0.03%0.97%2.09%
1 Month Performance61.85%2.12%7.36%11.13%
1 Year Performance-87.68%2.14%31.31%18.40%

Avenue Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATXI
Avenue Therapeutics
2.0686 of 5 stars
$0.42
+17.1%
N/A-89.8%$1.34MN/A0.024Trending News
MTNB
Matinas Biopharma
N/A$1.00
-2.9%
N/AN/A$5.09MN/A-0.2130
VIVS
VivoSim Labs
N/A$1.94
+0.0%
N/AN/A$5.04M$140K-0.1920Positive News
RDHL
Redhill Biopharma
N/A$2.18
-0.5%
N/A-99.0%$5.00M$8.04M0.00210News Coverage
Positive News
CNSP
CNS Pharmaceuticals
2.0325 of 5 stars
$0.88
+0.1%
$25.00
+2,755.5%
-98.4%$4.78MN/A0.005News Coverage
DRMA
Dermata Therapeutics
2.4424 of 5 stars
$0.73
+2.7%
$3.00
+311.5%
-65.7%$4.65MN/A-0.048
THAR
Tharimmune
3.2051 of 5 stars
$1.69
-2.3%
$17.00
+905.9%
-53.8%$4.50MN/A-0.212Positive News
SNGX
Soligenix
2.5958 of 5 stars
$1.36
+7.1%
N/A-80.1%$4.44M-$117.03K-0.3220Analyst Forecast
SPRB
Spruce Biosciences
2.4633 of 5 stars
$0.10
+15.3%
$1.75
+1,597.4%
-83.1%$4.35M$4.91M-0.1120Gap Down
CMND
Clearmind Medicine
0.9055 of 5 stars
$0.99
+4.0%
N/A-42.6%$4.22MN/A-0.90N/APositive News
REVB
Revelation Biosciences
0.9566 of 5 stars
$2.75
-1.4%
N/A-96.8%$4.21MN/A-0.0110

Related Companies and Tools


This page (NASDAQ:ATXI) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners